Evaluation of the RP-LC method for determining the pKa of abiraterone and its assay

• Autorzy: Senem Sanlı , Meryem Cansu Sahin , Ayse Özdemir , Buket Pasa

Identyfikatory

DOI

10.1556/1326.2023.01173

• Języki publikacji: EN

Abstrakty

EN

A straightforward, dependable, and quick RP-LC method for the analysis of abiraterone acetate in its dose form and human urine has been devised. With DAD detection, sensitivity was reported to be high. The LOD and LOQ of the procedure were deemed adequate. The suggested approach was exhaustively validated in accordance with ICH requirements, and the findings demonstrated that it was exact, accurate, selective, and sensitive for the analysis of this pharmaceutical. The chromatographic separation was realized using a X-Terra RP-18 (15034.60 mm i.d.35 μm) column and a UV detector set at 255 and 267 nm. In addition, pKa values were calculated based on the relationship between the retention factor and the pH of the mobile phase. The influence of the composition of the mobile phase on the ionization constant was investigated by measuring the pKa at various acetonitrile–water combinations ranging from 50 to 70% (v/v).

Słowa kluczowe

EN

abiraterone acetate; pKa value; nonlinear regression; internal standard; human urine

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2024
• Tom: Vol. 36, no. 4
• Strony: 355--362
• Opis fizyczny: Bibliogr. 38 poz., tab., wykr.

Twórcy

autor

Senem Sanlı

• Department of Medical Services and Techniques, Vocational School of Health Services, Usak University, Usak, Turkey

autor

Meryem Cansu Sahin

• Department of Medical Services and Techniques, Vocational School of Health Services, Usak University, Usak, Turkey

autor

Ayse Özdemir

• Department of Biochemisty, Faculty of Medicine, Usak University, Usak, Turkey

autor

Buket Pasa

• Department of Medical Services and Techniques, Vocational School of Health Services, Usak University, Usak, Turkey

Bibliografia

• 1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics. Cancer J. Clin. 2014, 64(1), 9–29. https://doi.org/10.3322/caac.21208.
• 2. Fizazi, K.; Scher, H. I.; Molina, A.; Logothetis, C.; Chi, K. N.; Jones, R.; Staffurth, J.; North, S.; Vogelzang, N.; Saad, F.; Mainwaring, P.; Harland, S.; Goodman, O.; Sternberg, C.; Li, J.; Kheoh, T.; Haqq, C.; Bono, J. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2012, 13(10), 983–92. https://doi.org/10.1016/s1470-2045(12)70379-0.
• 3. Rowlands, M. G.; Barrie, S. E.; Chan, F.; Houghton, J.; Jarman, M.; McCague, R.; Potter, G. A Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J. Med. Chem. 1995, 38(21), 4191–7. https://doi.org/10.1021/jm00021a008.
• 4. Hunt, N. J. Methanesulfonate salts of abiterone-3-esters and recovery of salts of Abiraterone one-3-esters from solution in methyl tetrabutyl ether, 2010, (United States). Pub. No. US 2010/0152437 A1.
• 5. Sonpavde, G.; Attard, G.; Bellmunt, J.; Mason, M. D.; Malavaud, B.; Tombal, B.; Sternberg, C. N. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur. Urol. 2011, 60(2), 270–8. https://doi.org/10.1016/j.eururo.2011.04.032.
• 6. Acharya, M.; Bernard, A.; Gonzalez, M.; Jiao, J.; De Vries, R.; Tran, N. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother. Pharmacol. 2012, 69(6), 1583–90. https://doi.org/10.1007/s00280-012-1865-3.
• 7. O’Donnell, A.; Judson, I.; Dowsett, M.; Raynaud, F.; Dearnaley, D.; Mason, M.; Harland, S.; Robbins, A.; Halbert, G.; Nutley, B.; Jarman, M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 2004, 90(12), 2317–25. https://doi.org/10.1038/sj.bjc.6601879.
• 8. Sarker, H.; Miksinski, S. United States food and drug administration, center for drug evaluation and research, chemistry review (S), application number: 202379, 2011. (United States Food and Drug Administration), Pub. No. 202379 Orig 1s000, NAD, 202379.
• 9. Pan, X.; Wang, H.; Li, C.; Zhang, J. Z. H; Ji, C. MolGpka: a Web server for Small molecule pK(a) prediction using a graph-convolutional neural Network. J. Chem. Inf. Model 2021, 61(7), 3159–65. https://doi.org/10.1021/acs.jcim.1c00075.
• 10. http://www.chemicalize.org. (2023). (Accessed 26 April 2023).
• 11. Arunkumar, S. G.; Radha, G. V. Analytical method development and validation for theestimation of Abiraterone acetate in pharmaceutical formulation by UV and RP-HPLC. Int. J. Pharm. Bio. Sci. 2016, 7(2), 57–61.
• 12. Latha, P. G.; Yunus, S. B.; Sree, N. B.; Naz, J.; Sagar, M.; Shine, S. A review on analytical methods for estimation of abiraterone acetate. World J. Pharm. Med. Res. 2016, 2, 23.
• 13. Reddy, B. J. C.; Sarada, N. J. Development and validation of a novel RP-HPLC method for stability-indicating assay of Abiraterone acetate. J. Liquid Chromatogr. & Relat. Tech. 2016, 39(7), 354–63. https://doi.org/10.1080/10826076.2016.1163500.
• 14. Gadhave, R. V.; Tamnar, B. A.; Bansode, S. A.; Choudhari, V. P. Stability indicating RP-HPLC-PDA method for determination of abıraterone acetate and characterization of its base catalyzed degradation product by LC-MS. Int. J. Pharm. Pharm. Sci. 2016, 8(2), 76–81.
• 15. Kavitapu, D.; Maruthapillai, A.; Mahapatra, S.; Selvi, J. A. New stability indicating RP-HPLC method for the determination of Abiraterone acetate, its related substances and degradation products in bulk and dosage form. Mater. Today Proc. 2021, 34, 469–78.
• 16. Sankar, P. R.; Eswarudu, M. M.; Siva, P.; Viswanath, A. Optimized and validated RP-HPLC method for quantification of abıraterone acetate (an antı- prostate cancer drug) in pharmaceutıcal dosage form. High Technol. Lett. 2021, 27(7), 21.
• 17. Alyamani, M.; Li, Z.; Upadhyay, S. K.; Anderson, D. J.; Auchus, R. J.; Sharifi, N. Development and validation of a novel LC-MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: innovation in separation of diastereoisomers without use of a chiral column. Steroid Biochem. Mol. Biol. 2017, 172, 231–9. https://doi.org/10.1016/j.jsbmb.2016.04.002.
• 18. Gurav, S.; Punde, R.; Farooqui, J.; Zainuddin, M.; Rajagopal, S.; Mullangi, R. Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. Biomed. Chromatogr. 2012, 26(6), 761–8. https://doi.org/10.1002/bmc.1726.
• 19. Khedra, A.; Darwish, I.; Bamanea, F. Analysis of abiraterone stress degradation behavior using liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry. J. Pharm. Biomed. Anal. 2013, 74, 77–82. https://doi.org/10.1016/j.jpba.2012.09.024.
• 20. van Nuland, M.; Hillebrand, M. J. X.; Rosing, H.; Schellens, J. H. M.; Beijnen, J. H. Development and validation of an LC-MS/MS method for the simultaneous quantification of abiraterone, enzalutamide, and their major metabolites in human plasma. Ther. Drug Monit. 2017, 39(3), 243– 51. https://doi.org/10.1097/ftd.0000000000000387.
• 21. Goud, V. M.; Rani, B. S.; Sharma, J. Development and validation for estimation of abiraterone acetate in bulk and pharmaceutical dosage form by UPLC. Res. J. Pharm. Tech. 2019, 12(6), 3029–32.
• 22. Gumustas, M.; Sanli, S.; Sanli, N.; Ozkan, S. A. Development and validation of a liquid chromatographic method for concurrent assay of weakly basic drug verapamil and amphoteric drug trandolapril in pharmaceutical formulations. J. Food Drug Anal. 2012, 20(3), 588–96. https://doi.org/10.6227/jfda.2012200304.
• 23. Sanli, N.; Sanli, S.; Sızır, U.; Gumustas, M.; Ozkan, S. A. Determination of pKa values of cefdinir and cefixime by LC and spectrophotometric methods and their analysis in pharmaceutical dosage forms. Chromatographia 2011, 73(11), 1171–6. https://doi.org/10.1007/s10337-011-2013-7.
• 24. Sanli, S.; Sanli, N.; Gumustas, M.; Karadas, N.; Aboul-Enien, H. Y. Simultaneous estimation of ceftazidime and ceftizoxime in pharmaceutical formulations by HPLC method. Chromatographia 2011, 74(7), 549–58. https://doi.org/10.1007/s10337-011-2116-1.
• 25. Rizzi, A.; Katz, E.; Eksteen, R.; Schoenmakers, P. J. Handbook of HPLC. (Ed.: Marcel Dekker): New York, 1998.
• 26. Sanli, N.; Fonrodona, G.; Barbosa, J.; Ozkan, G.; Beltran, J. L. Modelling retention in liquid chromatography of polyphenolic acids: prediction of solvent composition and pH of the mobile phase. Anal. Chim. Acta 2005, 537(1), 53–61. https://doi.org/10.1016/j.aca.2005.01.006.
• 27. Canals, I., II; Portal, J. A.; Bosch, E.; Roses, M. Retention of ionizable compounds on HPLC. 4. Mobile-phase pH measurement in methanol/water. Anal Chem. 2000, 72(8), 1802–9. https://doi.org/10.1021/ac990943i.
• 28. Sherrod, P. NLREG – nonlinear regression analysis and curve fitting program, 2007. http://www.nlreg.com.
• 29. Erdemgil, F.; S¸anli, S.; S¸anli, N.; Barbosa, J.; Guiteras, J.; Beltran, J.L. Determination of pKa values of some hydroxylated benzoic acids in methanol–water binary mixtures by LC methodology and potentiometry. Talanta 2007, 72(2), 489–96.
• 30. Ermer, J.; Miller, J. H. Method Validation in Pharmaceutical Analysis in A Guide to Best Practice; VCH, Wiley Pub: Germany, 2005.
• 31. Swartz, M. E.; Krull, I. S. Analytical Method Development and Validation; Marcel Dekker: New York, 1997.
• 32. Barbosa, J.; Fonrodona, G.; Marqués, I.; Sanz-Nebot, V.; Toro, I. Solvent effects on protonation equilibria of peptides and quinolones by factor analysis applied to the correlation between dissociation constants and solvatochromic parameters in acetonitrile-water mixtures. Anal. Chim. Acta 1997a, 351(1–3), 397–405.
• 33. Sanli, S.; Sanli, N. Determination of pKa values for some tyrosine kinase inhibitors using the reversed-phase liquid chromatography. J. Solution Chem. 2023, 52(6), 658–70. https://doi.org/10.1007/s10953-023-01264-5.
• 34. Yasuda, M. Dissociation constants of some carboxylic acids in mixed aqueous solvents. J. Bull. Chem. Soc. Jpn. 1959, 32(5), 429–32.
• 35. Shedlovsky, T. Electrolytes; Peasce, B., Ed. Pergamon Press: New York, 1962.
• 36. Barbosa, J.; Toro, I.; Sanz-Nebot, V. Acid-base behaviour of tripeptides in solvents used in liquid chromatography. Correlation between pK values and solvatochromic parameters of acetonitrilewater mixtures. Anal. Chim. Acta 1997b, 347(3), 295–304. https://doi.org/10.1016/S0003-2670(97)00163-3.
• 37. Sanli, N.; Sanli, S.; Özkan, G.; Denizli, A. Determination of pKa values of some sulfonamides by LC and LC-PDA methods in acetonitrile-water binary mixtures. J. Braz. Chem. Soc. 2010, 21, 1952–60.
• 38. CPMP/ICH/281/95 Note for Guidance on Validation of Analytical Procedure: Methodology, ICH Topic Q2B Validation of Analytical Procedure: Methodology, 1996. Step 4.